Is RPRX a buy or a sell?
The Discounted Cash Flow (DCF) valuation of Royalty Pharma PLC (RPRX) is 42.55 USD. With the latest stock price at 33.41 USD, the upside of Royalty Pharma PLC based on DCF is 27.3%. This means that RPRX is a buy according to the DCF valuation model.
| Range | Selected | |
| WACC / Discount Rate | 4.8% - 7.4% | 6.1% |
| Long-term Growth Rate | 2.5% - 4.5% | 3.5% |
| Fair Price | 18.59 - 385.43 | 42.55 |
| Upside | -44.4% - 1053.6% | 27.3% |